The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
Authors
Keywords
Osteosarcoma, PARP1, Olaparib, Doxorubicin, Prognosis
Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 37, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-05-21
DOI
10.1186/s13046-018-0772-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- FDA Approval of PARP Inhibitors and the Impact on Genetic Counseling and Genetic Testing Practices
- (2017) Kathryn M. Buchtel et al. Journal of Genetic Counseling
- The PARP-1 inhibitor Olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1+/- lymphoblastoid cells
- (2017) Emma C. Bourton et al. Journal of Cancer
- Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 and PARP2 with DNA double-strand break repair pathways
- (2016) Rajib Ghosh et al. DNA REPAIR
- PARP1 Links CHD2-Mediated Chromatin Expansion and H3.3 Deposition to DNA Repair by Non-homologous End-Joining
- (2016) Martijn S. Luijsterburg et al. MOLECULAR CELL
- Individual and Combined Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients
- (2016) Kyoung Min Kim et al. PLoS One
- PARP1 regulates the protein stability and proapoptotic function of HIPK2
- (2016) Jong-Ryoul Choi et al. Cell Death & Disease
- Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines
- (2015) Sonia Ávila-Arroyo et al. Journal of Breast Cancer
- Single molecule detection of PARP1 and PARP2 interaction with DNA strand breaks and their poly(ADP-ribosyl)ation using high-resolution AFM imaging
- (2015) Maria V. Sukhanova et al. NUCLEIC ACIDS RESEARCH
- Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma
- (2015) Michael Roth et al. PEDIATRIC BLOOD & CANCER
- Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients
- (2015) See-Hyoung Park et al. Translational Oncology
- Combined olaparib and oxaliplatin inhibits tumor proliferation and induces G2/M arrest and γ-H2AX foci formation in colorectal cancer
- (2015) Kaiwu Xu et al. OncoTargets and Therapy
- Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency
- (2015) Michal Kovac et al. Nature Communications
- The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma
- (2015) Dong Hyu Cho et al. Journal of Ovarian Research
- PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression
- (2015) Germano Mariano et al. Oncotarget
- DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma
- (2015) Alice N. Weaver et al. Oncotarget
- Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma
- (2015) Sonja J. Gill et al. PLoS One
- Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program
- (2014) M. A. Smith et al. CLINICAL CANCER RESEARCH
- Tumor-infiltrating PD1-Positive Lymphocytes and FoxP3-Positive Regulatory T Cells Predict Distant Metastatic Relapse and Survival of Clear Cell Renal Cell Carcinoma
- (2014) Myoung Jae Kang et al. Translational Oncology
- Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor
- (2013) Hideaki Ogiwara et al. CARCINOGENESIS
- Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival
- (2013) Alex Gan et al. HUMAN PATHOLOGY
- Combining PARP-1 Inhibition and Radiation in Ewing Sarcoma Results in Lethal DNA Damage
- (2013) Hae-June Lee et al. MOLECULAR CANCER THERAPEUTICS
- Expression of SIRT1 and DBC1 Is Associated with Poor Prognosis of Soft Tissue Sarcomas
- (2013) Jung Ryul Kim et al. PLoS One
- Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas
- (2013) Jung Ryul Kim et al. PLoS One
- PARP-1 protein expression in glioblastoma multiforme
- (2012) A. Galia et al. EUROPEAN JOURNAL OF HISTOCHEMISTRY
- New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
- (2012) Bryan A. Gibson et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- New targets and approaches in osteosarcoma
- (2012) Jonathan Gill et al. PHARMACOLOGY & THERAPEUTICS
- Activation of the ATM-Snail pathway promotes breast cancer metastasis
- (2012) Mianen Sun et al. Journal of Molecular Cell Biology
- Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer
- (2011) F. Rojo et al. ANNALS OF ONCOLOGY
- PARP and Cancer — If It's Broke, Don't Fix It
- (2011) Lisa A. Carey et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started